MMP-2, TIMP-1, E-cadherin, and β;-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium

Acta Obstetricia et Gynecologica Scandinavica

Volumn 87, Issue 8, 2008, Pages 868-874

  Shaco Levy, Ruthy ^a   Sharabi, Shalom ^b   Piura, Benjamin ^a   Sion Vardy, Netta ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

catenin; E cadherin; Endometrial endometrioid carcinoma; Endometrial serous carcinoma; Matrix metalloproteinases

Indexed keywords

BETA CATENIN; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SEROUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 49649096620     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802253775     Document Type: Article

References (24)

1. Monaghan H, MacWhinnie N, Williams ARW. The role of matrix metalloproteinases-2, -7, and -9 and β-catenin in high grade endometrial carcinoma. Histopathology. 2007;50:348-57.
2. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology. 1998;33:297-308.
3. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260-7.
4. Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: A clinicopathological study of 40 cases. Mod Pathol. 2005;18:75-82.
5. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993;71:1368-83.
6. Chang C, Werb Z. The many faces of metalloproteinases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11:S37-43.
7. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002;94:1466-75.
8. Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Darai E. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer. 2006;16:1911-7.
9. Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J Cell Biol. 1994;125:1327-40.
10. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, et al. Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol. 1991;139:17-23.
11. Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003;199:471-8.
12. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15:1032-7.
13. Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004;10:5546-53.
14. Scholten AN, Aliredjo R, Creutzberg CL, Smit VTHBM. Combined E-cadherin, β-catenin, and β-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer. 2006;16:1379-85.
15. Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol. 2002;100:1290-5.
16. Demopoulos RI, Mesia AF, Mittal K, Vamvakas E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: Clues to pathogenesis. Int J Gynecol Pathol. 1999;18:233-7.
17. Athanassiadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiadou AM, Stamati PN, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: A prospective immunocytochemical study. Int J Gynecol Cancer. 2007;17:697-704.
18. Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: A clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-78.
19. Iurlaro M, Loverro G, Vacca A, Cormio G, Ribatti D, Minischetti M, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest. 1999;29:793-801.
20. Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol. 1997;28:220-6.
21. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: A clinical-pathological correlation study. Ann Oncol. 2006;17:637-45.
22. Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E, Kudo R. Nuclear localization of β-catenin in normal and carcinogenic endometrium. Mol Carcinog. 1999;25:207-18.
23. Behrens J, Von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996;382:638-42.
24. Scholten AN, Creutzberg CL, van den Broek LJCM, Noordijk EM, Smit VTHBM. Nuclear β-catenin is a molecular feature of type I endometrial carcinoma. J Pathol. 2003;201:460-5.